In late October 2014, ViaCyte implanted the first VC-01 product candidate in a human patient with type 1 diabetes. As ViaCyte CEO Paul Laikind, Ph.D., put it: “To our knowledge, this is the first time that an embryonic stem cell-derived cell replacement therapy for diabetes has been studied in human subjects.”
The achievement was a culmination of at least 10 years of work by the ViaCyte team, along with collaborators and supporters at the California Institute for Regenerative Medicine (CIRM) and the JDRF.
A number of media outlets and organization covered the historic milestone. While cautious, each expressed optimism and hope for the therapy, a much-needed advance for a chronic disease that disrupts the lives of millions of people.
Read more from: